Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Pharma Biz Leaders Say New Price Cut Rule for Long-Listed Products a Painful Blow
January 10, 2014
- Daiichi Sankyo Submits NDA for Edoxaban in US
January 10, 2014
- Novartis Issues Apologies after Complaint Filing over Diovan, Vows Cooperation with Authorities
January 10, 2014
- Proposal to Reduce Basic Fees for Medical Institutions with Low Price Agreement Rates Could Have Big Impact: Mr Kono of Toho Pharmaceutical
January 10, 2014
- New IFN-Free Oral Drugs for Chronic Hepatitis C Could Create New Market
January 10, 2014
- MTPC Sets Up Medway Business Management Office Eyeing Resumption of Medway Injection Production
January 9, 2014
- Baxter Seeks Japan Approval of Recombinant Factor IX for Hemophilia B
January 9, 2014
- Takeda Initiates PIII Trials of Vedolizumab in Japan; Filing Expected in FY2017
January 9, 2014
- Daiichi Sankyo Applies for European Approval of Edoxaban
January 9, 2014
- Former Pfizer EPBU Head Matsumori Joins SBI Biotech as President
January 8, 2014
- Astellas Ties Up with ClearPath in US to Invest in RSV Vaccine Development
January 8, 2014
- NBI Files Additional Indication of Asthma for Spiriva
January 7, 2014
- Eisai Launches Epilepsy Treatment Fycompa in US
January 7, 2014
- Astellas to Transfer Fermentation Research-Related Assets to Taiho
January 7, 2014
- New Price Cut Rule for Long-Listed Products Blow to Drug Makers
January 6, 2014
- Azilva Tops SOC Ranking for Second Month in a Row in November in Both Hospital and GP Markets: Anterio
January 6, 2014
- Novartis Seeks Japanese Regulatory Approval of Psoriasis Agent Secukinumab
January 6, 2014
- Shionogi, AZ Revise Royalty Rate for Crestor
January 6, 2014
- Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
- Nissan Chemical Sues Seven Generic Companies over Livalo Patents
December 27, 2013
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…